CAMKV and ovarian carcinoma: Antibody-profiling serum from healthy controls (n = 35), benign controls (n = 12) and ovarian cancer patients across four disease subtypes (n = 80) using the custom protein array showed detectable autoantibodies (Z-score > 0) against all antigens except CAMKV and MAGEB10 (n = 48/50).